Probiotics and Perimenopause: What the Research Actually Shows

Walk into any pharmacy looking for something to help with perimenopause, and you will be greeted by an entire wall of supplements promising to fix all of your problems. Somewhere in that wall, nestled between the tinctures of essential oils and the semi-suspicious “hormone balance” blends which are pink-washed to be $5 more expensive, you will find probiotics. Unlike some of their neighbours on that shelf, probiotics come with a growing body of research behind them. While there is evidence to believe probiotics do something, like all things regarding women’s health, the research is messier and more nuanced than the marketing would have you believe. The sources are all linked, so you can read them for yourself.

Probiotics are living microorganisms, typically bacteria, which have some sort of health benefit when consumed in adequate amounts. Essentially, they are helpful bacteria, similar to what is found in naturally fermented foods like yogurt, kimchi, and kefir. Different species and strains of bacteria can behave very differently in the body, so “taking a probiotic” is a bit like saying “taking a medication.” One important caveat of probiotics worth mentioning is that they do not permanently alter your gut microbiome. Studies suggest that they need to be administered regularly to have an ongoing effect, and the benefits usually taper off when supplementation stops. This isn’t a reason to dismiss them, but it is a reason to be skeptical of anyone marketing a probiotic as a one-time fix.

Before getting into specific symptoms, it’s worth understanding why the gut microbiome matters so much during perimenopause. The male and female gut microbiomes are measurably different, and the female microbiome changes after menopause, becoming less diverse and compositionally distinct from the microbiomes of premenopausal women. The reason for this, as with many elements of perimenopause, is estrogen. Estrogen and the gut microbiome have a bidirectional relationship. Estrogen shapes which bacteria thrive in the gut, and the bacteria in turn help regulate estrogen levels in the body. The mechanism responsible for the latter effect involves a group of bacterial genes called the estrobolome. When estrogen has finished circulating in the bloodstream, it is sent to the liver, which tags on molecules to estrogen to make it biologically inactive. This biologically inactive form of estrogen is then excreted into the gut, where bacteria can remove the tag and reactivate it, allowing it to be absorbed into the bloodstream once more. This means that the gut microbiome essentially acts as an estrogen recycling system. A well functioning estrobolome helps maintain more stable circulating estrogen levels, which becomes increasingly important when the ovaries are producing less estrogen during perimenopause. When the gut microbiome is disrupted (a state called dysbiosis), this recycling process becomes less efficient, which can worsen the hormonal fluctuations that make perimenopause so unpredictable.

Osteoporosis is one of the more serious long-term consequences of estrogen loss, with women estimated to lose 2-2.5% of bone mass annually in the first five years following menopause. While there is still much to be investigated, current research on probiotics and bone health shows promising results. The bacteria Lactobacillus helveticus has been shown to increase serum calcium (the calcium circulating in your blood) compared to conventional milk, and Lactobacillus reuteri has been shown to reduce the loss of tibia bone mineral density in older women with low bone density. The exact mechanism behind this effect is still unknown, but probiotics appear to work on bone health partially through anti-inflammatory pathways. Inflammation promotes the activity of the cells responsible for breaking down bone, and several probiotic strains have been shown to suppress these inflammatory signals, therefore reducing bone loss. That being said, probiotics still have a considerably smaller effect than traditional osteoporosis medications such as bisphosphonates, so they should not be used in lieu of practitioner-recommended treatment.

The estrobolome’s role in regulating estrogen recycling also has direct implications for cancer risk. One study on postmenopausal women found that greater microbial diversity in the gut microbiome was associated with higher production of estrogen metabolites hydroxylated at the 2 and 4 positions, which have been associated with a lower risk of breast cancer. Interestingly, the connection of gut microbiome diversity and breast cancer is different for premenopausal women. Premenopausal women with breast cancer have been found to have similar gut microbiomes to premenopausal women without breast cancer, while menopausal women with breast cancer show a distinctly different gut microbiome compared to postmenopausal healthy controls. These results suggest that the gut-estrogen relationship becomes more relevant as estrogen production decreases during perimenopause and menopause. It’s important to note, however, that this area of research is still new, and the current microbiome findings reflect associations rather than causality.

The vaginal microbiome undergoes significant changes during perimenopause, as declining estrogen reduces the glycogen-rich environment that Lactobacillus species require to live. As Lactobacillus abundance decreases, vaginal pH rises, and the risk of bacterial vaginosis and recurrent UTIs increases. Lactobacillus-based probiotics, administered either orally or vaginally, have shown evidence of restoring Lactobacillus populations and reducing vaginal pH. One clinical trial found that probiotic supplementation reduced inflammatory markers in postmenopausal women by 40-80%, with a 50% improvement in overall vaginal health index scores. While these results are only from a single study and warrant replication, they suggest real potential.

A recent randomized controlled trial investigated the effect of Lactobacillus acidophilus supplementation on sexual function in perimenopausal and menopausal women with sexual dysfunction, using questionnaires to measure outcomes before and after eight weeks of supplementation. The probiotic group showed significant improvements in sexual desire and arousal compared to the placebo group. There were, however, no significant changes in the ability to reach orgasm or levels of pain during sex. This is a notable finding, as it suggests probiotics can have influence on some components of sexual function. Further research is required into the exact mechanism of this effect, as questionnaires rely on self-reporting, which may not be fully accurate.

Hot flashes and night sweats are not something you’d immediately associate with gut bacteria. But the research says otherwise.

For GSM specifically, the evidence suggests probiotics may be most effective as an adjunct to, rather than a replacement for, estrogen therapy. Oral or vaginal probiotics in menopausal women have shown to be effective in reducing GSM symptoms, and the combination of probiotics with estrogen appears to outperform estrogen alone. A systematic review of Lactobacillus-based interventions for GSM found preventative effects for recurrent cystitis (bladder inflammation) in non-randomized studies, though randomized controlled trials showed more mixed results. This is a recurring theme in literature as it relates to probiotics: results look promising in smaller trials and observational studies, but are harder to replicate in larger more controlled trials, suggesting that the effect isn’t as black-and-white as we might think.

Perhaps the most surprising area of research involves vasomotor symptoms such as hot flashes and night sweats, which you wouldn’t immediately associate with gut bacteria. A systematic review of 39 studies involving over 3,000 women reported that probiotics positively affected menopausal and perimenopausal symptoms including vasomotor symptoms, vaginal dryness, and mental health. One specific study found that 12 weeks of Lactobacillus acidophilus supplementation significantly reduced overall menopausal symptom scores, including hot flashes, anxiety, depression, and vaginal dryness. The mechanism is not fully understood, but likely involves the estrobolome’s role in modulating circulating estrogen levels, as well as the communication system between the gut microbiome and the brain that influences serotonin production, among other neurotransmitters.

The research on probiotics and perimenopause is promising, despite being limited in many areas. Strain specificity matters enormously: Lactobacillus reuteri 6475 has been specifically studied for bone health, Lactobacillus acidophilus has the most data for menopausal symptoms and sexual function, and vaginal Lactobacillus strains are most relevant to GSM. A generic probiotic off the pharmacy shelf may contain none of these strains in meaningful concentrations.

Probiotics are not a substitute for evidence-based treatments like local estrogen therapy for GSM, hormone therapy for severe vasomotor symptoms, or bisphosphonates for significant osteoporosis. What they may offer is a relatively low-risk complementary option, especially for those who cannot or do not wish to use hormonal therapies, with a biologically plausible mechanism and a growing clinical evidence base. The honest summary is this: there is enough evidence toward the benefits of probiotics to be interesting, not quite enough to be certain of anything concrete, and more than enough to justify further research. For a condition as prevalent and as undertreated as perimenopause, that is not nothing.

There is enough evidence toward the benefits of probiotics to be interesting, not quite enough to be certain of anything concrete, and more than enough to justify further research.

The key sources behind this piece, for anyone who wants to read further:

• Patel M, Atluri LM, Gonzalez NA, et al. A systematic review of mixed studies exploring the effects of probiotics on gut-microbiome to modulate therapy in children with autism spectrum disorder. Cureus, 2022.
• Barrea L, Verde L, Auriemma RS, et al. Probiotics and prebiotics: any role in menopause-related diseases? Current Nutrition Reports, 2023.
• Resciniti SM, Biesiekierski JR, Ghasem-Zadeh A, Moschonis G. The effectiveness of a Lactobacilli-based probiotic food supplement on bone mineral density and bone metabolism in Australian early postmenopausal women: protocol for a double-blind randomized placebo-controlled trial. Nutrients, 2024.
• Nilsson AG, Sundh D, Bäckhed F, Lorentzon M. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. Journal of Internal Medicine, 2018.
• Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. Journal of the National Cancer Institute, 2016.
• Zhu J, Liao M, Yao Z, et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome, 2018.
• Andrews RAF, Lacey A, Roach H, Tomlinson R, Kidd EJ, Bache K. Investigating the effects of probiotics during the menopause transition: a systematic review and meta-analysis. Clinical Nutrition ESPEN, 2025.
• Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus, 2020.
• Vicariotto F, Malfa P, Viciani E, et al. Efficacy of Lactiplantibacillus plantarum PBS067, Bifidobacterium animalis subsp. lactis BL050, and Lacticaseibacillus rhamnosus LRH020 in the amelioration of vaginal microbiota in post-menopausal women: a prospective observational clinical trial. Nutrients, 2024.
• Valizadeh R, Borhani F, Shabani F, Mirghafourvand M. The effect of probiotic supplementation on sexual function in premenopausal and menopausal women: a randomized controlled clinical trial. Scientific Reports, 2025.
• Tsuboi I, Inoue S, Maruyama Y, Mitsui Y, Hirakawa H, Araki M, Sadahira T. Effect of Lactobacillus-based probiotics on genitourinary syndrome of menopause in post-menopausal women: a systematic review. Maturitas, 2026.
• Lim EY, Lee SY, Shin HS, et al. The effect of Lactobacillus acidophilus YT1 (MENOLACTO) on improving menopausal symptoms: a randomized, double-blinded, placebo-controlled clinical trial. Journal of Clinical Medicine, 2020.

This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for personal medical guidance.